Ensartinib for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial provides access to ensartinib, an oral medication that targets a specific genetic change in non-small cell lung cancer (NSCLC). It is for people who cannot join other clinical trials for ensartinib and may help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer that tests positive for the ALK gene change.
- You are not able to join other clinical trials for ensartinib.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- You can swallow and keep down oral medication.
- You agree to use two effective forms of birth control (if applicable) during treatment and for 90 days after.
- You have adequate organ function, and any brain metastases are either treated and stable or not causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments after lung cancer surgery: a new targeted drug (ensartinib) versus standard chemotherapy. The goal is to see if the targeted drug helps prevent the cancer from coming back.
This trial tests the drug ensartinib to shrink lung cancer before surgery. It is for people with ALK-positive lung cancer that can be surgically removed.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial tests different targeted therapies after surgery to lower the risk of early-stage lung cancer returning. It's designed for patients with high-risk features, and the treatment depends on the genetic changes in the tumor.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests a targeted therapy pill called ensartinib for people with advanced solid tumors (other than lung cancer) that have an ALK or MET gene change. The drug works by blocking signals that help these cancers grow, and the study aims to see how well it works and if it's safe.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.